1273 results about "Excipient" patented technology

The invention relates to the field of biotechnology and female health care, in particular to a stachyose composition for promoting micro-ecological regulation of lactobacillus and application of the stachyose composition, and the composition comprises stachyose and pharmaceutically acceptable auxiliary materials. The stachyose is used as prebiotics to selectively promote proliferation and colonization of the lactobacillus crispatus, the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can promote proliferation of the lactobacillus crispatus, the lactobacillus crispatus is one or more of the lactobacillus crispatus, the lactobacillus plantarum and the lactobacillus acidophilus, and the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can inhibit gardnerella and candida albicans. The stachyose composition disclosed by the invention is in the form of slow-release gel and bath foam; the composition can be used for treating or preventing bacterial vaginitis, colpitis mycotica and related symptoms, has the advantages of no antibiotics, no drug resistance, high safety and the like, and is suitable for the fields of vagina local nursing and micro-ecological regulation.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention relates to the technical field of female private care, and discloses a long-acting antibacterial female care gel and a preparation method thereof.According to the care gel, natural plant extracts serve as core active ingredients, microbial fermentation products, macromolecular thickening agents and functional auxiliary materials are supplemented, and a synergistic system is formed through scientific compatibility; wherein the core components comprise compound antibacterial components such as cranberry extract, gallnut extract and pomegranate peel extract, nourishing and repairing components such as radix puerariae extract and southern dodder seed extract, and stable components such as ammonium polyacryloyldimethyl taurine. By optimizing the formula composition and the preparation process, the technical problems that existing female care gel is short in bacteriostasis time and poor in biocompatibility are solved, and the female care gel has the multiple effects of long-acting bacteriostasis, mildness, no irritation, nourishing, repairing, moisturizing, lubricating and the like. The preparation method adopts the processes of segmented extraction, gradient mixing and low-temperature sterilization, ensures the stability of active ingredients and the uniformity of a gel system, and is suitable for large-scale production.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and / or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.

The invention discloses a colchicine external preparation with high intradermal residual quantity and percutaneous transmittance as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The invention provides a colchicine external preparation with high intradermal residue and transdermal transmittance. The colchicine external preparation comprises: a) colchicine or a pharmaceutically acceptable salt thereof; b) a penetration enhancer; c) pharmaceutically acceptable excipients and / or excipients; the penetration enhancer is at least one of polyglycerol oleate or isosorbide dimethyl ether. The drug loading capacity and the percutaneous transmittance of the colchicine external preparation disclosed by the invention are remarkably improved. When polyglycerol oleate is selected as a penetration enhancer to prepare colchicine gel, the intradermal retention volume can reach 358.08 micrograms within 20 hours. When isosorbide monomethyl ether is selected as a penetration enhancer to prepare ethosome gel, the accumulated penetration amount can reach 106.87 mu g / cm < 2 >, and the intradermal residual amount can reach 90.58 mu g or above.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine spray for treating rhinitis and a preparation method thereof.The traditional Chinese medicine spray is prepared from flos magnoliae liliflorae, fructus xanthii, herba ephedrae, fructus forsythiae, flos lonicerae, radix angelicae, herba asari, menthol, herba centipedae and herba menthae. Refining to obtain a fluid extract; and mixing the fluid extract with a penetration enhancer consisting of aminoketone and menthol, a sodium hyaluronate mucous membrane repairing agent, a pH regulator, an isoosmotic adjusting agent and a preservative to prepare spray liquid medicine, and finally performing sterile filtration and filling. Through efficient extraction and synergism of composite auxiliary materials, the permeability and bioavailability of the medicine are remarkably improved, and the symptoms such as nasal obstruction and running nose can be quickly relieved; meanwhile, the anti-inflammatory function and the function of actively repairing the damaged nasal mucosa are achieved, and the recurrence rate is reduced from the source; the pH and osmotic pressure of the preparation are precisely adjusted, the use is comfortable, and the quality is stable and controllable.

The invention relates to the field of pharmaceutical preparations, and particularly discloses an amorphous-state tigorazan tablet and a preparation method thereof. The amorphous-state tigorazan tablet comprises a tablet and a coating material in a weight ratio of 100: (2-4), the tablet comprises the following raw materials: amorphous-state tigorazan, a carrier inclusion material, an excipient, a disintegrating agent, a lubricant and a flow aid, the dosage of the amorphous-state tigorazan is 20-30% of the total mass of all the raw materials of the tablet, and the dosage of the carrier inclusion material is 20-30% of the total mass of all the raw materials of the tablet. The weight ratio of the amorphous tigoran to the carrier inclusion material is 1: (0.80-1.15), and the carrier inclusion material is vitamin E polyethylene glycol succinate. The amorphous tigorazan tablet provided by the invention not only has higher solubility and dissolution rate, but also has higher stability and better hardness and friability, not only improves the bioavailability of drugs, but also avoids the use of organic solvents, simplifies the production process, reduces the risks of production safety and environmental protection, and is suitable for large-scale industrial production.

The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.

Disclosed are a peptide amide compound composition, a preparation method therefor and medical use thereof. Specifically, the composition contains a compound of formula (I) and pH regulators, and the pH of the solution thereof is 3-5.5. The composition is stable and requires few excipients, and is stable in clinical use. The composition is used for treating or preventing a disease or condition associated with kappa opioid receptors

Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.

The invention provides a compound as shown in a formula I which can be used as a sodium channel regulator, and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition containing the compound and the stereoisomer, the tautomer or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

The invention relates to the technical field of medical instruments, in particular to a paclitaxel drug coating balloon dilatation catheter and a preparation method and application thereof.The paclitaxel drug coating comprises a substrate layer, a middle layer and an outer layer; the substrate layer comprises paclitaxel and a hydrophilic excipient; the middle layer comprises a lipophilic excipient and a temperature response type polymer; and the outer layer comprises a pH sensitive polymer. The substrate layer is combined with the surface of the balloon, so that excellent conveying stability is provided, the medicine is effectively prevented from falling off prematurely in the conveying process of the catheter, and the firmness of the coating is improved; a micropore network structure is formed in the middle layer, the network structure is expanded under the body temperature condition, the porosity is increased, slow release of the medicine is achieved, the absorption amount of the medicine on the blood vessel wall is effectively increased, and the medicine effect time is prolonged; the solubility of the outer layer is improved in a slightly acidic blood vessel wall environment, so that the release of the medicine is further promoted, and the effective release of the medicine on the blood vessel wall is ensured.

The invention discloses traditional Chinese medicine suspension eye drops and a preparation method thereof, and the traditional Chinese medicine suspension eye drops are prepared from the following raw materials in parts by weight: 1-3 parts of a traditional Chinese medicine composition, 4-7 parts of hydroxypropyl-beta-cyclodextrin, 0.5-2 parts of microcrystalline cellulose-sodium carboxymethyl cellulose and auxiliary materials. The traditional Chinese medicine suspension eye drops provided by the invention abandon a traditional eye ointment form, are directly dropped for use, are convenient to use, have good stability and dispersity, and are excellent in use curative effect and medication experience; on the basis of keeping the clinical efficacy of the Marcher eight-treasure ancient prescription, secondary development and research are scientifically carried out, so that the Marcher eight-treasure ancient prescription plays a greater clinical treatment role, and has a wider market development prospect.

The invention discloses a processing method of wine-processed rhizoma polygonati, which belongs to the technical field of traditional Chinese medicine processing, and comprises the following steps: selecting rhizoma polygonati, cleaning, slicing and drying; spraying an acidic compound solution, steaming for the first time, preserving heat, moistening, and collecting a steaming solution; after finishing and slicing, spraying catalytic compound liquid prepared from steaming liquid and auxiliary materials, steaming for the second time, and preserving heat and moistening; then steaming at normal pressure for the third time; and finally, pre-drying at low temperature, heating and finally drying, and inspecting to obtain a wine rhizoma polygonati finished product. According to the invention, a segmented precise regulation and control system is constructed, so that the used functional additive can be completely removed, and the purity and safety of the product are guaranteed; the compound liquid proportion, spraying parameters and steaming key indexes are defined, systematic control standards are formed, the problem of quality fluctuation of traditional processing is solved, the product appearance and taste are better, the key indexes stably exceed the pharmacopoeia standard, and upgrading from experience and technology to standardized production is achieved.

The invention relates to an absorbable bone hemostasis and repair stent. The absorbable bone hemostasis and repair stent comprises the following raw materials in parts by weight: 15-60 parts of an excipient, 15-60 parts of a softening agent and 5-70 parts of a bone repair promoting component, the excipient is prepared from a polyoxyethylene-polyoxypropylene copolymer; the softening agent comprises a semi-solid mobile phase polymer; the bone repair promoting component comprises a coating and a core, the coating comprises a polylactic acid-glycolic acid copolymer, zinc stearate and potassium bromide, the core comprises calcium phosphate particles, and the coating wraps the surface of the core. The preparation method comprises the following steps: preparing the bone repair promoting component; and preparing the absorbable bone hemostasis repair stent. The absorbable bone hemostasis and repair stent is high in hemostasis and collapse resistance and has good inflammation regulation and bone repair promoting effects. The absorbable bone hemostasis and repair stent can be used for bone hemostasis and bone repair promotion of any bone injury wound.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant adeno-associated virus of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical compositions may be useful in gene therapy for the treatment of PA caused by mutations in propionyl-CoA carboxylase α-subunit (PCCA) or mutations in propionyl-CoA carboxylase β-subunit (PCCB).

The present invention relates to formulations of glucagon analogues or pharmaceutically acceptable salts and / or derivatives thereof; and their medical use, e.g. in the treatment of hypoglycemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising a combination of excipients that make them suitable for long-term storage as liquids and capable of being used in single dose (SD) or multiple dose (MD) formulations.

An injectable cannabidiol formulation for non-IV parenteral administration comprising, consisting essentially of, or consisting of: (a) a solvent system consisting of (i) an effective amount of at least one triglyceride oil; and (ii) an effective amount of at least one C1-C3 alkyl ester of a C6-C22 fatty acid; and (b) an effective amount of cannabidiol; wherein the formulation is free of water and ethanol, has a viscosity less than about 35 cP, and is phase stable and chemically stable. The formulation can further comprise at least one additional pharmaceutically acceptable excipient. Kits containing the formulation are also described.

This invention belongs to the technical field of medicinal chemistry and provides a milrinone-tartaric acid cocrystal. Using Cu-Kα radiation, its X-ray diffraction pattern (expressed as 2θ) exhibits characteristic peaks at at least 10.0±0.2°, 13.2±0.2°, 20.4±0.2°, 24.7±0.2°, 26.2±0.2°, 26.7±0.2°, and 34.3±0.2°. The cocrystal of this invention has high solubility and good stability. Using this cocrystal to prepare formulations avoids the use of large amounts of excipients and auxiliaries in existing technologies, reducing both production costs and clinical safety risks. The preparation method of the milrinone-tartaric acid cocrystal provided by this invention is simple to operate, the crystallization process is easy to control, and it has good reproducibility.

This invention belongs to the field of pharmaceutical formulation technology and provides a vinpocetine suspension and its preparation method. The vinpocetine suspension of this invention comprises the following raw materials in specific mass parts: vinpocetine, a suspending agent, a solubilizer, a stabilizer, and water. The vinpocetine suspension of this invention is suitable for oral administration. The excipients in the suspension include a suspending agent, a solubilizer, and a stabilizer. The solubilizer inhibits the aggregation of vinpocetine nanoparticles and improves the solubility and dispersion uniformity of vinpocetine nanoparticles in water. The suspending agent and stabilizer together construct a spatially stable structure, ensuring the suspension and dispersion of vinpocetine nanoparticles and resisting sedimentation. The suspending agent, solubilizer, and stabilizer work synergistically to achieve nanoscale distribution and uniform dispersion and suspension of vinpocetine, significantly improving the bioavailability of vinpocetine. High-pressure homogenization achieves nanoscale distribution of vinpocetine, with a particle size of 200-300 nm.

To provide AHR agonist compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat immune-mediated diseases.SOLUTION: A pharmaceutical composition comprising a compound of the formula: wherein R1 is selected from phenyl, C1-C6 alkyl, C3-C6 cycloalkyl, 5-6 membered heteroaryl optionally substituted with 1-2 R I, and the like; R2 is selected from H and OH; X is selected from a bond, -C (R3) 2 -, and -C (R3) 2C (R3) 2 -; Y is selected from -C (R3) 2 -, -O, and -N (R j) -; R3 is independently selected from H and C1-C3 alkyl; R I is selected from halogen, CH3, OCH3, and CF3; R j is C1-C3 alkyl; or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable carriers, diluents or excipients.SELECTED DRAWING: None

This invention relates to a low-irritation soothing composition and its application, belonging to the technical field of skin care products. The low-irritation soothing composition, by weight percentage, comprises 0.05–0.2 wt% kava soothing agent, 0.3–1.0 wt% pine nut extract, 1.8–2.5 wt% a mixed emulsifier composed of cetearyl alcohol and glyceryl stearate, wherein the mass ratio of cetearyl alcohol to glyceryl stearate is 2.5–3.5:1; 2.0–5.0 wt% moisturizer, 0.4–1.0 wt% preservative, 0–2.0 wt% cosmetically acceptable excipients, and the balance being water. This invention utilizes the synergistic effect of low concentrations of kava soothing agent and pine nut extract, and employs a low total fat emulsification system to form a delicate and stable O / W emulsion, reducing transepidermal water loss and repairing the physical barrier; together, they maintain a low-inflammatory, low-oxidative, and microbial balanced microenvironment, providing ideal conditions for barrier repair.

The invention relates to a detection method, in particular to a method for rapidly detecting alpha and beta-lactoglobulin in auxiliary material lactose based on a microarray chip technology. On the basis of an indirect competitive enzyme-linked immunosorbent assay principle and a silver enhanced developing technology, a high-sensitivity microarray chip detection platform is successfully constructed by virtue of a biological chip scanner, and rapid quantitative analysis of alpha-lactalbumin and beta-lactoglobulin in the auxiliary material lactose for injection is realized. According to the method, an antigen-antibody specific recognition mechanism and a nano-silver signal amplification mechanism are integrated, and the detection efficiency and sensitivity are remarkably improved through the high-throughput layout of the microarray chip. In the aspect of methodology performance, the technology has the remarkable advantages of simple and convenient operation process, short detection time, high sample treatment flux, excellent specificity (CRlt; 1%) and the like.

The present invention relates to an oral extract composition comprising Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) extract composition, and its process of preparation. Also relates to the oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient for, improvement, and maintenance of women health more preferably in improving of hot flashes, night sweats, poor sleep, anxiety, sexual dysfunction, mood changes, Genitourinary symptoms in overall improving the quality of life, serum estradiol, progesterone, follicle stimulating hormone (FSH), and cortisol during the period of menopause (perimenopause and menopause). The oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient is used for improving Brain-derived neurotrophic factor (BDNF) levels in women during the period of menopause. The present invention, further related to the extraction process of Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.), also provides the process for the preparation of formulation composition. This invention further relates to the extraction process from Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) either as individual herbs or co-extraction of the two herbs or mixing the extracts at various stages of the individual extracts.

Disclosed are an mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one early-secreted antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof; PE / PPE family antigen WAG22 of Mycobacterium tuberculosis or an immunologically active fragment thereof; and at least one latent-related antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which may serve as a prophylactic vaccine for preventing latent activation or as a therapeutic drug for treating active tuberculosis, exhibiting a significant inhibitory effect on Mycobacterium tuberculosis.

The invention belongs to the technical field of Fuzhuan tea processing, and discloses a Fuzhuan tea composition which comprises the following components in parts by weight: 20-40 parts of a Fuzhuan tea extracting solution, 1-3 parts of menthol, 5-10 parts of xylitol, 10-20 parts of glycerol, 1-5 parts of a surfactant, 3-8 parts of a dendrobium officinale extract, 2-6 parts of a rose extract, 5-10 parts of a cassia seed extract, 0.3-0.8 part of a safflower extract, 3-7 parts of a chrysanthemum extract and medical-grade auxiliary materials, wherein the medical-grade auxiliary material comprises 5-15 parts of moisturizer glycerol. According to the invention, the application of the Fuzhuan tea is expanded from traditional drinks to daily necessities for eye care, a new product which can effectively relieve eyestrain, is mild in texture and can effectively provide moisture for fragile skin around eyes is developed, and the product provides a new form of health efficacy of using the Fuzhuan tea for consumers; a brand-new growth track is opened up for the Fuzhuan tea industry, and development, utilization and industrial upgrading of the Fuzhuan tea are effectively promoted.

This invention discloses a highly active compound health supplement made from Cordyceps sinensis, Artemisia argyi, and rhubarb, and its preparation method, belonging to the field of health food and pharmaceutical preparation processing technology. The method includes: adding artificial Cordyceps sinensis ultrafine powder, prepared Rhubarb tanguticum fine powder, Artemisia argyi leaf extract, microcrystalline cellulose PH102, and maltodextrin into a mixer and premixing at 25-35 rpm to allow the powder to adhere to the surface of the excipients; after tableting, the tablets are subjected to ultra-high pressure treatment at 350-380 MPa. This invention achieves uniform distribution and performance optimization of the formulation components without damaging the activity of heat-sensitive components through precise coupling of premixing strength and ultra-high pressure modification parameters. Experiments show that the obtained formulation has an adenosine retention rate ≥96%, a dissolution rate ≥85% after 5 minutes, and excellent moisture resistance and mechanical strength, solving the technical problems of large activity loss, easy moisture absorption, and slow dissolution in traditional formulations.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.